In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

Overview of attention for article published in Retrovirology, February 2015

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source

twitter: 1 X user

Citations

dimensions_citation: 35 Dimensions

Readers on

mendeley: 51 Mendeley

Summary Policy documents X Dimensions citations

So far, Dimensions has found 35 publications that cite this research output.

35

The most recent citing publications are shown below. View all 35 publications that cite this research output on Dimensions.

Dolutegravir-based Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 (HIV-2) Infection: Progress for People With HIV-2

Article in Clinical Infectious Diseases (June 2023)

Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study

Article in Clinical Infectious Diseases (June 2023)

Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds

Article in International Journal of Molecular Sciences (March 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.